What is Adalimumab?

Adalimumab is a fully human monoclonal antibody that targets tumor necrosis factor-alpha (TNF-α), a key inflammatory cytokine involved in the pathogenesis of numerous autoimmune and inflammatory conditions. As one of the most commercially successful biologic medications, it has transformed the treatment landscape for multiple chronic inflammatory diseases.

Indications

Adalimumab is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, juvenile idiopathic arthritis, and non-infectious uveitis. It is typically used when conventional therapies have been inadequate.

Dosage

For rheumatoid arthritis: 40 mg subcutaneously every other week. For Crohn disease: Induction dose of 160 mg, then 80 mg at week 2, then 40 mg every other week. For psoriasis: 80 mg initial dose, then 40 mg every other week starting one week after initial dose.

Warnings

Adalimumab increases the risk of serious infections, including tuberculosis. Patients must be screened for latent TB before initiating therapy. There is also an increased risk of lymphoma and other malignancies. Live vaccines should not be administered during treatment. The medication should be discontinued if a serious infection develops.